Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the British Society for Rheumatology Biologics Register in Rhematoid Arthritis (BSRBR-RA)
Authors' conclusion
In one of the largest analyses of patients with RA, biologic-naïve RA patients treated with etanercept originator showed similar outcomes vs biosimilar using real-world data. Drug survival, and disease activity after 6 and 12 months of therapy, was similar between cohorts.
Study context
- Population
- Biologic-naïve RA patients starting etanercept in the BSRBR-RA from 2010, routine clinical practice in the UK
- Participants
- 1,806 patients
- Exposure
- Etanercept originator vs etanercept biosimilar as first biologic in RA
- Originatorn = 1,009
- Biosimilarn = 797reference
- Outcome
- DAS28 remission, EULAR response and MCID in function
- Follow-up
- 6 and 12 months
Methodological detailsregistry-based (BSRBR-RA), propensity-decile adjustment, multiple imputation
- Registry-based (BSRBR-RA)
- Propensity-decile adjustment
- Multiple imputation
Main finding
As reported in the abstract
DAS28 remission and EULAR response
- Proportion achieving DAS28 remission and EULAR response similar between treatments
Observational data: associations, not effects.
Further findings
Drug survival (remaining on therapy) · 1 year · patients censored at time of switch
| Outcome | Originator | Biosimilar |
|---|---|---|
| Switch from originator onto etanercept biosimilar during follow-up | 19% | — not stated in the abstract |
— not stated in the abstract
Drug survival (remaining on therapy) · 1 year
- Originator patients no more likely to stop therapy vs biosimilar
Original publication
Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA. Rheumatology (Oxford). Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →